Bifogade filer
Kurs
+2,74%
Likviditet
54,3 MNOK
Kalender
Est. tid* | ||
2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-14 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-28 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2025-05-27 | - | Årsstämma |
2025-05-08 | - | Kvartalsrapport 2025-Q1 |
2025-02-13 | - | Bokslutskommuniké 2024 |
2024-11-06 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-06-26 | - | Årsstämma |
2024-06-06 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-02-01 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-06-07 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2023-06-06 | - | Årsstämma |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-02 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-06-23 | - | Årsstämma |
2022-05-27 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-01-27 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-21 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2021-05-20 | - | Årsstämma |
2021-04-22 | - | Kvartalsrapport 2021-Q1 |
2021-01-28 | - | Bokslutskommuniké 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-08-19 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2020-05-14 | - | Årsstämma |
2020-04-23 | - | Kvartalsrapport 2020-Q1 |
2020-01-30 | - | Bokslutskommuniké 2019 |
2020-01-06 | - | Extra Bolagsstämma 2020 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-15 | - | Kvartalsrapport 2019-Q2 |
2019-05-16 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2019-05-15 | - | Årsstämma |
2019-04-30 | - | Kvartalsrapport 2019-Q1 |
2019-01-30 | - | Bokslutskommuniké 2018 |
2018-10-18 | - | Kvartalsrapport 2018-Q3 |
2018-08-16 | - | Kvartalsrapport 2018-Q2 |
2018-05-09 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2018-05-07 | - | Årsstämma |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-02-01 | - | Bokslutskommuniké 2017 |
2017-10-19 | - | Kvartalsrapport 2017-Q3 |
2017-08-17 | - | Kvartalsrapport 2017-Q2 |
2017-05-12 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2017-05-11 | - | Årsstämma |
2017-04-27 | - | Kvartalsrapport 2017-Q1 |
2017-02-02 | - | Bokslutskommuniké 2016 |
2016-10-26 | - | Kvartalsrapport 2016-Q3 |
2016-08-17 | - | Kvartalsrapport 2016-Q2 |
2016-05-12 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2016-05-11 | - | Årsstämma |
2016-04-19 | - | Kvartalsrapport 2016-Q1 |
2016-02-11 | - | Kapitalmarknadsdag 2016 |
2016-02-11 | - | Bokslutskommuniké 2015 |
2015-11-03 | - | Kvartalsrapport 2015-Q3 |
2015-08-13 | - | Kvartalsrapport 2015-Q2 |
2015-05-13 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2015-05-12 | - | Årsstämma |
2015-05-05 | - | Kvartalsrapport 2015-Q1 |
2015-02-17 | - | Bokslutskommuniké 2014 |
2014-11-05 | - | Kvartalsrapport 2014-Q3 |
2014-08-13 | - | Kvartalsrapport 2014-Q2 |
2014-05-15 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2014-05-14 | - | Årsstämma |
2014-04-30 | - | Kvartalsrapport 2014-Q1 |
2014-02-14 | - | Bokslutskommuniké 2013 |
2013-11-01 | - | Kvartalsrapport 2013-Q3 |
2013-08-09 | - | Kvartalsrapport 2013-Q2 |
2013-06-13 | - | Kapitalmarknadsdag 2013 |
2013-05-28 | - | X-dag ordinarie utdelning |
2013-05-27 | - | Årsstämma |
2013-05-07 | - | Kvartalsrapport 2013-Q1 |
2013-02-01 | - | Extra Bolagsstämma 2013 |
2013-01-07 | - | Bokslutskommuniké 2012 |
2012-11-06 | - | Kvartalsrapport 2012-Q3 |
2012-08-10 | - | Kvartalsrapport 2012-Q2 |
2012-05-07 | - | X-dag ordinarie utdelning AZT 0.00 NOK |
2012-05-07 | - | Årsstämma |
2012-05-07 | - | Kvartalsrapport 2012-Q1 |
2012-02-21 | - | Bokslutskommuniké 2011 |
2011-11-08 | - | Kvartalsrapport 2011-Q3 |
2011-08-10 | - | Kvartalsrapport 2011-Q2 |
2011-05-13 | - | Årsstämma |
2011-05-13 | - | Kvartalsrapport 2011-Q1 |
2011-05-12 | - | X-dag ordinarie utdelning |
2011-02-17 | - | Bokslutskommuniké 2010 |
2010-11-12 | - | Kvartalsrapport 2010-Q3 |
2010-08-10 | - | Kvartalsrapport 2010-Q2 |
2010-05-11 | - | Kvartalsrapport 2010-Q1 |
2010-05-04 | - | Årsstämma |
2010-03-03 | - | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Bioteknik |
Tromsø, Norway, 28. May 2020 - Biotec Pharmacon (OSE: Biotec) announces its subsidiary, ArcticZymes AS, has been granted by Innovation Norway up to NOK 1.6 million for a project to commercialize additional enzyme components required by diagnostic developers.
ArcticZymes Cod UNG enzyme offers diagnostic developers a superior enzyme-based solution for preventing false-positive results without affecting sensitivity in molecular diagnostic tests. Since the commercialization of Cod UNG in 2004, the enzyme has been integrated into a broad range of diagnostic tests by commercial partners. Furthermore, Cod UNG has been essential for many companies developing and marketing molecular diagnostic tests to detect RNA viruses such as HIV and Hepatitis C virus (HCV).
Following the Covid-19 outbreak, ArcticZymes has experienced upsides in sales with numerous companies who have integrated Cod UNG into their COVID-19 diagnostic tests. Beyond Cod UNG, viral diagnostic developers have repeatedly expressed the need for additional enzyme components not currently offered by ArcticZymes. Examples include high-grade DNA polymerases and reverse transcriptases, which are integral to PCR, LAMP and other amplification technologies. Such technologies will drive innovation of the second generation of COVID-19 diagnostic tests by commercial partners.
In the pursuit to provide a more complete commercial offering, ArcticZymes aims to supply all essential enzyme components to viral diagnostic developers. In supporting this initiative, the project will broaden and accelerate the company's capacity to innovate and commercialize such enzymes without compromising the existing product development pipeline. The project is estimated to be completed within 18 months.
ArcticZymes AS, CEO, Jethro Holter said:
"ArcticZymes have been a critical supplier to viral diagnostic companies for over a decade with Cod UNG representing our lead product. The main commercial objectives of this project are twofold. First it is to build other core enzymes around Cod UNG specific to viral diagnostics which can be exploited in the second generation of COVID-19 diagnostic tests and tests for future emerging viruses. Secondly, it expands ongoing innovation efforts towards achieving ArcticZymes strategic goal in becoming Europe's leading one-stop-shop for enzymes.
We are grateful to Innovation Norway for supporting the project and recognizing the valuable contribution ArcticZymes is making towards improving infectious disease healthcare."
Thomas Stien, Financial Advisor, Innovation Norway, added:
"As part of the Norwegian government's efforts to limit the effects of the coronavirus eruption, Innovation Norway has been given an increased limit for innovation grants aimed at companies with growth ambitions. The grant will help companies continue to pursue good innovation projects - or facilitate new ones.
We prioritize innovation projects that have great utility, high degree of innovation and likelihood of success. This product development meets a specific need in the global market and will contribute to strengthening ArcticZymes competitiveness. In addition, it will most likely result in more jobs in the region."
-ENDS-
For more information, please contact:
Dr Jethro Holter, CEO Tel: +47 46 85 91 46
Email: Jethro.Holter@biotec.no
About Biotec Pharmacon ASA
Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.
The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsø to offer niche and high-tech products in several biotech segments.
For more information, please visit the website: www.biotec.no (https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.biotec.no%2F&data=02%7C01%7Cborge.sorvoll%40biotec.no%7C431a745110544076f55408d7fc9f16b7%7C50ad6b59f39b4622803bb98e5ea50c8f%7C0%7C1%7C637255632517610211&sdata=%2BJHy1cAGERiP%2FE4udmIubCdGUJWvF4%2Ba3vG%2FROtHMac%3D&reserved=0).
About ArcticZymes AS
ArcticZymes develops, produces and markets novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
The Company focuses on novel and high-quality enzyme technologies in growth markets where rapid technological developments are creating a strong demand for new and improved enzymes. Some of its enzymes' unique features include heat lability and activity in challenging environments as well as customized, engineered novel features which can be integrated to power the technologies of commercial partners.
All ArcticZymes products are ISO13485 certified.
For more information, please visit: www.arcticzymes.com (https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.arcticzymes.com%2F&data=02%7C01%7Cborge.sorvoll%40biotec.no%7C431a745110544076f55408d7fc9f16b7%7C50ad6b59f39b4622803bb98e5ea50c8f%7C0%7C1%7C637255632517620209&sdata=%2FjzawYVtx9yQybb5y7rlZA06NoIRuQz5lkgTja%2BY5eg%3D&reserved=0)